Northwest Biotherapeutics (NWBO) Amortization of Deferred Charges (2014 - 2021)
Northwest Biotherapeutics (NWBO) posted quarterly Amortization of Deferred Charges of $76000.0 for Q1 2026, up 18.75% year-over-year from $64000.0 in Q1 2025, and up 4.11% quarter-over-quarter from $73000.0 in Q4 2025.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Amortization of Deferred Charges (2014 - 2021) Analysis & Trends
Northwest Biotherapeutics' Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $76000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 18.75% year-over-year to $76000.0; the TTM figure through Mar 2026 stood at $285000.0 (down 0.7% YoY), while the FY2025 annual figure was $273000.0, down 9.0% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $76000.0, up from $73000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $82000.0 in Q2 2024, with the low at $63000.0 in Q3 2022.
- The 5-year median for Amortization of Deferred Charges is $71000.0 (2023), against an average of $71000.0.
- The sharpest annual moves came in 2025 and 2026: Amortization of Deferred Charges fell 19.51% in 2025, then increased 18.75% in 2026.
- Northwest Biotherapeutics' Amortization of Deferred Charges stood at $63000.0 in 2022, then increased by 15.87% to $73000.0 in 2023, then slipped by 12.33% to $64000.0 in 2024, then grew by 14.06% to $73000.0 in 2025, then climbed by 4.11% to $76000.0 in 2026.
- Business Quant data shows NWBO's Amortization of Deferred Charges at $76000.0 in Q1 2026, $73000.0 in Q4 2025, and $70000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 57,000.00 |
| Jun 30, 2021 | 56,000.00 |
| Mar 31, 2021 | 93,000.00 |
| Dec 31, 2020 | 89,000.00 |
| Sep 30, 2020 | 86,000.00 |
| Jun 30, 2020 | 83,000.00 |
| Mar 31, 2020 | 80,000.00 |
| Dec 31, 2019 | -757,000.00 |
| Sep 30, 2019 | 213,000.00 |
| Jun 30, 2019 | 196,000.00 |
| Mar 31, 2019 | 26,000.00 |
| Dec 31, 2016 | 211,000.00 |
| Sep 30, 2016 | 208,000.00 |
| Jun 30, 2016 | 222,000.00 |
| Mar 31, 2016 | 209,000.00 |
| Dec 31, 2015 | 235,000.00 |
| Sep 30, 2015 | 296,000.00 |
| Jun 30, 2015 | 483,000.00 |
| Mar 31, 2015 | 234,000.00 |
| Dec 31, 2014 | 162,000.00 |